New weight loss shot TE-8105 tested in early human trial
NCT ID NCT06471530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called TE-8105 in 38 overweight or obese adults without diabetes. The main goal was to see if the drug is safe and how the body processes it. Participants received one or more injections of TE-8105 at different doses. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TE-8105
- What this could lead to
- If it works, this could point toward a new treatment for weight loss in people who are overweight or obese.
- What could go wrong
- This is a very early, first-in-human trial with only 38 participants. It is designed mainly to check safety and dosing, not to prove weight loss works. Many early-stage drugs fail to show benefit in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?